WeeklyTrail A story, an idea, a topic…Ctrl K

World

W

MHRA approved lurbinectedin in September 2026 for adults with extensive-stage small cell lung cancer

The UK regulator reported on 23 September 2026 that it had approved lurbinectedin (Zepzelca) with atezolizumab as maintenance treatment for adults with extensive-stage small cell lung cancer whose disease had not progressed after first-line induction therapy.

WeeklyTrail contextual illustration
WeeklyTrail contextual illustration
Read in feed1 min readWeeklyTrail:

Search

Saved

Saved in this browser

Discussion